Download PDF
Thromb Haemost 2001; 86(01): 386-394
DOI: 10.1055/s-0037-1616236
Research Article
Schattauer GmbH

Plasma Lipoproteins, Hemostasis and Thrombosis

John H. Griffin
1   Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA
,
José A. Fernández
1   Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA
,
Hiroshi Deguchi
1   Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
12 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Regulation of hemostasis and thrombosis involves numerous plasma factors that contribute to procoagulant and anticoagulant pathways. Lipid-containing surfaces provide sites where both procoagulant and anticoagulant enzymes, cofactors and substrates are assembled to express their activities. Plasma and lipoproteins can contribute to either procoagulant or anticoagulant reactions. Procoagulant lipids/lipoproteins include triglyceride-rich particles in plasma and oxidized low density lipoprotein (LDL) which can accelerate activation of prothrombin, factor X and factor VII. Potentially anticoagulant lipids and lipoproteins, each of which enhances inactivation of factor Va by activated protein C, include phosphatidylethanolamine, cardiolipin, the neutral glycosphingolipids glucosylceramide and Gb3 ceramide (CD77), and high density lipoprotein (HDL). Remarkably, treatment of hyperlipidemia with statins not only lowers lipids but also provides antithrombotic effects whose mechanisms remain to be clarified. We hypothesize that procoagulant and anticoagulant lipids and lipoproteins in plasma may contribute to a Yin-Yang balance that helps influence the up-regulation and down-regulation of thrombin generation.

Key words

Lipoprotein - glycolipid - glucosylceramide - protein C - prothrombinase
 

  • References

  • 1 Miller GJ. Lipoproteins and the haemostatic system in atherothrombotic disorders. Baillieres Best Pract Res Clin Haematol 1999; 12: 555-75.
    CrossrefPubMedGoogle Scholar
  • 2 Miller GJ. Postprandial lipaemia and haemostatic factors. Atherosclerosis 1998; 141: S47-51.
    CrossrefPubMedGoogle Scholar
  • 3 Mitropoulos KA, Miller GJ, Reeves BEA, Wilkes HC, Cruickshank JK. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis 1989; 76: 203-8.
    CrossrefPubMedGoogle Scholar
  • 4 Mitropoulos KA, Reeves BEA, O’Brien DP, Cooper JA, Martin JC. The relationship between factor VII coagulant activity and factor XII activation induced in plasma by endogenous or exogenously added contact surface. Blood Coag Fibrinol 1993; 4: 223-34.
    CrossrefPubMedGoogle Scholar
  • 5 Silveira A, Karpe F, Blombäck M, Steiner G, Walldius G, Hamsten A. Activation of coagulation factor VII during alimentary lipemia. Arterioscler Thromb 1994; 14: 60-9.
    CrossrefPubMedGoogle Scholar
  • 6 Miller GJ, Martin JC, Mitropoulos KA, Esnouf MP, Cooper JA, Morrissey JH, Howarth DJ, Tuddenham EG. Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency. Blood 1996; 87: 4187-96.
    PubMedGoogle Scholar
  • 7 Miller GJ, Mitropoulos KA, Nanjee MN, Howarth DJ, Martin JC, Esnouf MP, Reeves BE, Miller NE, Cooper JA. Very low activated factor VII and reduced factor VII antigen in familial abetalipoproteinaemia. Thromb Haemost 1998; 80: 233-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Zito F, Drummond F, Bujac SR, Esnouf MP, Morrissey JH, Humphries SE, Miller GJ. Epidemiological and genetic associations of activated factor XII concentration with factor VII activity, concentration, and risk of coronary heart disease in men. Circulation 2000; 102: 2058-62.
    CrossrefPubMedGoogle Scholar
  • 9 MacCallum PK, Cooper JA, Martin J, Howarth DJ, Meade TW, Miller GJ. Haemostatic and lipid determinants of prothrombin fragment F1.2 and D-dimer in plasma. Thromb Haemost 2000; 83: 421-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Mariani G, Bernardi F, Bertina R, Vicente VV, Prydz H, Samama M, Sandset PM, Di Nucci GD, Testa MG, Bendz B, Chiarotti F, Ciarola MV, Strom R. Serum phospholipids are the main environmental determinants of activated factor VII in the most common FVII genotype. European Union Concerted Action “Clotart”. Haematologica 1999; 84: 620-6.
    PubMedGoogle Scholar
  • 11 Mariani G, Conard J, Bernardi F, Bertina R, Vicente Garcia V, Prydz H, Samama M, Sandset PM, Puopolo M, Ciarla MV, Poso R, Di Nucci GD, Ceci F, Marchetti G. Oral contraceptives highlight the genotype-specific association between serum phospholipids and activated Factor VII. Arterioscler Thromb Vasc Biol 1999; 19: 2024-8.
    CrossrefPubMedGoogle Scholar
  • 12 Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. JAMA 1998; 279: 1643-50.
    CrossrefPubMedGoogle Scholar
  • 13 Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-313.
    CrossrefPubMedGoogle Scholar
  • 14 Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997; 17: 265-72.
    CrossrefPubMedGoogle Scholar
  • 15 Szczeklik A, Musial J, Undas A, Gajewski P, Gora P, Swadzba J, Jankowski M. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 1999; 33: 1286-93.
    CrossrefPubMedGoogle Scholar
  • 16 Dangas G, Smith DA, Unger AH, Shao JH, Meraji P, Fier C, Cohen AM, Fallon JT, Badimon J, Ambrose JA. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost 2000; 83: 688-92.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Fenton JW, Shen GX, Minnear FL, Brezniak DV, Jeske WP, Walenga JM, Bognacki J, Ofosu FA, Hassouna HI. Statin drugs and dietary isoprenoids as antithrombotic agents. Hematol Oncol Clin North Am 2000; 14: 483-90.
    CrossrefPubMedGoogle Scholar
  • 18 Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000; 132: 689-96.
    PubMedGoogle Scholar
  • 19 Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95: 1517-32.
    PubMedGoogle Scholar
  • 20 Goodnight SH, Griffin JH. Herditary thrombophilia. Chapter 127. In: Williams’ Hematology 6th edition. Beutler E, Lichtman MA, Coller B, Kipps TJ, Seligsohn U. eds. New York: McGraw Hill; 2000: 1697-714.
    Google Scholar
  • 21 Kawasaki T, Kambayashi J, Ariyoshi H, Sakon M, Suehisa E, Monden M. Hypercholesterolemia as a risk factor for deep-vein thrombosis. Thromb Res 1997; 88: 67-73.
    CrossrefPubMedGoogle Scholar
  • 22 Nowak-Göttl U, Junker R, Hartmeier M, Koch HG, Munchow N, Assmann G, von Eckardstein. Increased lipoprotein (a) is an important risk factor for venous thromboembolism in childhood. Circulation 1999; 100: 743-8.
    CrossrefPubMedGoogle Scholar
  • 23 von Depka M, Nowak-Göttl U, Eisert R, Dieterich C, Bartheis M, Scharrer I, Ganser A, Ehrenforth S. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 2000; 96: 3364-8.
    PubMedGoogle Scholar
  • 24 Deguchi H, Fernández JA, Pabinger I, Heit JA, Griffin JH. Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Blood 2001; 97: 1907-14.
    CrossrefPubMedGoogle Scholar
  • 25 Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999; 340: 1555-64.
    CrossrefPubMedGoogle Scholar
  • 26 Gross PO, Aird WC. The endothelium and thrombosis. Semin Thromb Haemost 2000; 26: 463-78.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 MacFarlane RG. An enzyme cascade in the blood clotting mechanism and its function as a biological amplifier. Nature 1964; 202: 498-9.
    CrossrefPubMedGoogle Scholar
  • 28 Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 1310-1.
    CrossrefPubMedGoogle Scholar
  • 29 Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-70.
    CrossrefPubMedGoogle Scholar
  • 30 Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53: 505-18.
    CrossrefPubMedGoogle Scholar
  • 31 Lammle B, Griffin JH. Formation of the fibrin clot: the balance of procoagulant and inhibitory factors. Clin Haematol 1985; 14: 281-342.
    PubMedGoogle Scholar
  • 32 Broze Jr GJ. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46: 103-12.
    CrossrefPubMedGoogle Scholar
  • 33 Bouma BN, dem Borne PA, Meijers JC. Factor XI and protection of the fibrin clot against lysis – a role for the intrinsic pathway of coagulation in fibrinolysis. Thromb Haemost 1998; 80: 24-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Owen WG, Esmon CT. Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1981; 256: 5532-5.
    PubMedGoogle Scholar
  • 35 Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269: 26486-91.
    PubMedGoogle Scholar
  • 36 Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA 1996; 93: 10212-6.
    CrossrefPubMedGoogle Scholar
  • 37 Mitchell CA, Kelemen SM, Salem HH. The anticoagulant properties of a modified form of protein S. Thromb Haemost 1988; 60: 298-304.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 1993; 268: 2872-7.
    PubMedGoogle Scholar
  • 39 Heeb MJ, Rosing J, Bakker HM, Fernandez JA, Tans G, Griffin JH. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci U S A 1994; 91: 2728-32.
    CrossrefPubMedGoogle Scholar
  • 40 Hackeng TM, van t’ Veer C, Meijers JCM, Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem 1994; 269: 21051-8.
    PubMedGoogle Scholar
  • 41 van’t Veer C, Hackeng TM, Biesbroeck D, Sixma JJ, Bouma BN. Increased prothrombin activation in protein S-deficient plasma under flow conditions on endothelial cell matrix: An independent anticoagulant function of protein S in plasma. Blood 1995; 85: 1815-21.
    PubMedGoogle Scholar
  • 42 Koppelman SJ, Hackeng TM, Sixma JJ, Bouma BN. Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII. Blood 1995; 86: 1062-71.
    PubMedGoogle Scholar
  • 43 Bernard GR, Vincent J-L, Laterre P-F, LaRosa SP, Dhainaut J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher Jr CJ. for the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group.. Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis. New Engl J Med 2001; 344: 699-709.
    CrossrefPubMedGoogle Scholar
  • 44 Rao LV, Rapaport SI. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 1987; 69: 645-51.
    PubMedGoogle Scholar
  • 45 Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze Jr GJ. Cloning and characterization of a cDNA coding for the lipoprotein- associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001-4.
    PubMedGoogle Scholar
  • 46 Lesnik P, Vonica A, Guerin M, Moreau M, Chapman MJ. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arterioscler Thromb 1993; 13: 1066-75.
    CrossrefPubMedGoogle Scholar
  • 47 Rapaport SI, Rao LVM. The tissue factor pathway: how it has become a “prima ballerina.”. Thromb Haemost 1995; 74: 7-17.
    PubMedGoogle Scholar
  • 48 Baugh RJ, Broze Jr GJ, Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J Biol Chem 1998; 273: 4378-86.
    CrossrefPubMedGoogle Scholar
  • 49 Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances Factor Va inactivation by activated protein C. J Biol Chem 1994; 269: 816-9.
    PubMedGoogle Scholar
  • 50 Safa O, Hensley K, Smirnov MD, Esmon CT, Esmon NL. Lipid oxidation enhances the function of activated protein C. J Biol Chem 2001; 276: 1829-36.
    CrossrefPubMedGoogle Scholar
  • 51 Fernandez JA, Kojima K, Petaja J, Hackeng TM, Griffin JH. Cardiolipin enhances protein C pathway anticoagulant activity. Blood Cell Mol Dis 2000; 26: 115-23.
    CrossrefPubMedGoogle Scholar
  • 52 Bradley WA, Gianturco SH. Vitamin K-dependent proteins bind to very low-density lipoproteins. Semin Thromb Hemost 1988; 14: 253-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 53 De Sousa JC, Soria C, Ayrault-Jarrier M, Pastier D, Bruckert E, Amiral J, Bereziat G, Caen JP. Association between coagulation factors VII and X with triglyceride rich lipoproteins. J Clin Pathol 1988; 41: 940-4.
    CrossrefPubMedGoogle Scholar
  • 54 Silveira A, Karpe F, Blombäck M, Steiner G, Walldius G, Hamsten A. Activation of coagulation factor VII during alimentary lipemia. Arterioscler Thromb 1994; 14: 60-9.
    CrossrefPubMedGoogle Scholar
  • 55 Moyer MP, Tracy RP, Tracy PB, van’t Veer C, Sparks CE, Mann KG. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler Thromb Vasc Biol 1998; 18: 458-65.
    CrossrefPubMedGoogle Scholar
  • 56 Rota S, McWilliam NA, Baglin TP, Byrne CD. Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: Modulation by oxidation and vitamin E. Blood 1998; 91: 508-15.
    PubMedGoogle Scholar
  • 57 Xu N, Öhlin AK, Zhou L, Nilsson Å. Binding of prothrombin to chyle chylomicrons: effects of temperature and calcium ions, and role of surface phospholipids. Thromb Res 1995; 80: 35-46.
    CrossrefPubMedGoogle Scholar
  • 58 Xu N, Dahlbäck B, Öhlin AK, Nilsson Å. Association of vitamin K-dependent coagulation proteins and C4b binding protein with triglyceride-rich lipoproteins of human plasma. Arterioscler Thromb Vasc Biol 1998; 18: 33-9.
    CrossrefPubMedGoogle Scholar
  • 59 Saenko EL, Shima M, Sarafanov G. Role of activation of the coagulation Factor VIII in interaction with vWf, phospholipid, and functioning within the Factor Xase complex. Trends Cardiovascular Med 1999; 9: 185-92.
    CrossrefPubMedGoogle Scholar
  • 60 Kjalke M, Silveira A, Hamsten A, Hedner U, Ezban M. Plasma lipoproteins enhance tissue factor-independent factor VII activation. Arterioscler Thromb Vasc Biol 2000; 20: 1835-41.
    CrossrefPubMedGoogle Scholar
  • 61 Griffin J, Kojima K, Banka CL, Curtiss LK, Fernandez JA. High density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999; 103: 219-27.
    CrossrefPubMedGoogle Scholar
  • 62 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
    CrossrefPubMedGoogle Scholar
  • 63 Griffin JH, Evatt B, Wideman C, Fernández JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
    PubMedGoogle Scholar
  • 64 Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina R. Venous thrombosis due to poor anticoagulant response to activated protein C. Leiden thrombophilia study. Lancet 1993; 342: 1503-6.
    CrossrefPubMedGoogle Scholar
  • 65 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
    CrossrefPubMedGoogle Scholar
  • 66 Greengard JS, Sun X, Xu X, Fernández JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1361-2.
    PubMedGoogle Scholar
  • 67 Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten Cate JW, Mertens K, van Mourik JA. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994; 343: 1535-6.
    CrossrefPubMedGoogle Scholar
  • 68 Fisher M, Fernández JA, Ameriso SF, Xie D, Gruber A, Paganini-Hill A, Griffin JH. Activated protein C resistance in ischemic stroke not due to factor V arginine506 glutamine mutation. Stroke 1996; 27: 1163-6.
    CrossrefPubMedGoogle Scholar
  • 69 van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Meijer P, de Jong PT, Hofman A, Grobbee DE, Kluft C. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Inter Med 1996; 125: 265-9.
    CrossrefPubMedGoogle Scholar
  • 70 Sakata T, Kario K, Katayama Y, Matsuyama T, Kato H, Miyata T. Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state. Thromb Res 1996; 82: 235-44.
    CrossrefPubMedGoogle Scholar
  • 71 de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-6.
    PubMedGoogle Scholar
  • 72 Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130: 643-50.
    CrossrefPubMedGoogle Scholar
  • 73 Sampram ES, Lindblad B, Dahlbäck B. Activated protein C resistance in patients with peripheral vascular disease. J Vasc Surg 1998; 28: 624-9.
    CrossrefPubMedGoogle Scholar
  • 74 Kiechl S, Muigg A, Santer P, Mitterer M, Egger G, Oberhollenzer M, Oberhollenzer F, Mayr A, Gasperi A, Poewe W, Willeit J. Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. Circulation 1999; 99: 614-9.
    CrossrefPubMedGoogle Scholar
  • 75 Pajkrt D, Lerch PG, van der Poll T, Levi M, Illi M, Doran JE, Arnet B, van den Ende A, ten Cate JW, van Deventer SJ. Differential effects of reconsituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia. Thromb Haemost 1997; 77: 303-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 76 Li D, Weng S, Yang B, Zander DS, Saldeen T, Nichols WW, Khan S, Mehta JL. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler Thromb Vasc Biol 1999; 19: 378-83.
    CrossrefPubMedGoogle Scholar
  • 77 Naqvi TZ, Shah PK, Ivey PA, Molloy MD, Thomas AM, Panicker S, Ahmed A, Cercek B, Kaul S. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am J Cardiol 1999; 84: 1011-7.
    CrossrefPubMedGoogle Scholar
  • 78 Ichikiwa S, Hirabayshi Y. Glucosylceramide synthase and glycosphingolipid synthesis. Trends in Cell Biology 1998; 8: 198-202.
    CrossrefPubMedGoogle Scholar
  • 79 Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387: 569-72.
    CrossrefPubMedGoogle Scholar
  • 80 Brown DA, London E. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 1998; 14: 111-36.
    CrossrefPubMedGoogle Scholar
  • 81 Jacobson K, Dietrich C. Looking at lipid rafts?. Trends Cell Biol 1999; 9: 87-91.
    CrossrefPubMedGoogle Scholar
  • 82 Brown DA, London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem 2000; 275: 17221-4.
    CrossrefPubMedGoogle Scholar
  • 83 Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood 1992; 79: 2340-8.
    PubMedGoogle Scholar
  • 84 Heeb MJ, Gruber A, Griffin JH. Identification of divalent metal ion-dependent inhibition of activated protein C by 2-macroglobulin and 2-antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin and plasmin. J Biol Chem 1991; 266: 17606-12.
    PubMedGoogle Scholar
  • 85 Okajima K, Koga S, Kaji M, Inoue M, Nakagaki T, Funatsu A, Okabe H, Takatsuki K, Aoki N. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Thromb Haemost 1990; 63: 48-53.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 86 Snow TR, Deal MT, Dickey DT, Esmon CT. Protein C activation following coronary artery occlusion in the in situ porcine heart. Circulation 1991; 84: 293-9.
    CrossrefPubMedGoogle Scholar
  • 87 Macko RF, Killewich LA, Fernandez JA, Cox DK, Gruber A, Griffin JH. Brain-specific protein C activation during carotid artery occlusion in humans. Stroke 1999; 30: 542-5.
    CrossrefPubMedGoogle Scholar
  • 88 Petaja J, Pesonen E, Fernandez JA, Vent AE, Ramo OJ, Griffin JH. Cardiopulmonary bypass and activation of antithrombotic plasma protein C. J Thorac Cardiovasc Surg 1999; 118: 422-9.
    CrossrefPubMedGoogle Scholar
  • 89 Comp PC, Jacocks RM, Ferrell GL, Esmon CT. Activation of protein C in vivo. J Clin Invest 1982; 70: 127-34.
    CrossrefPubMedGoogle Scholar
  • 90 Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest 1993; 92: 2003-12.
    CrossrefPubMedGoogle Scholar
  • 91 Griffin JH. The thrombin paradox. Nature 1995; 378: 337-8.
    CrossrefPubMedGoogle Scholar
  • 92 Lentz SR, Fernandez JA, Griffin JH, Piegors DJ, Erger RA, Malinow MR, Heistad DD. Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the protein C system. Arterioscler Thromb Vasc Biol 1999; 19: 1744-50.
    CrossrefPubMedGoogle Scholar
  • 93 Mitropoulos KA, Reeves BE, Miller GJ. The activation of factor VII in citrated plasma by charged long-chain saturated fatty acids at the interface of triglyceride-rich lipoproteins. Blood Coag Fibrinolysis 1993; 4: 943-51.
    CrossrefPubMedGoogle Scholar
  • 94 Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989; 339: 301-3.
    CrossrefPubMedGoogle Scholar
  • 95 Harpel PC, Hermann A, Zhang X, Ostfeld I, Borth W. Lipoprotein(a), plasmin modulation, and atherogenesis. Thromb Haemost 1995; 74: 382-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 96 Ishibashi S. Lipoprotein(a) and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1-2.
    CrossrefPubMedGoogle Scholar
  • 97 Angles-Cano E. High antifibrinolytic activity of lipoprotein(a) containing small apolipoprotein(a) isoforms. Circulation 2000; 102: 184-5.
    CrossrefPubMedGoogle Scholar
  • 98 Okumura K, Iseki K, Wakugami K, Kimura Y, Muratani H, Ikemiya Y, Fukiyama K. Low serum cholesterol as a risk factor for hemorrhagic stroke in men: a community-based mass screening in Okinawa, Japan. Jpn Circ J 1999; 63: 53-8.
    CrossrefPubMedGoogle Scholar
  • 99 Leppala JM, Virtamo J, Fogelholm R, Albanes D, Heinonen OP. Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. Stroke 1999; 30: 2535-40.
    CrossrefPubMedGoogle Scholar